Sugi Predict

Sugi Predict / Targets / MSR1

MSR1

Macrophage scavenger receptor types I and II · P21757 · MSR1 on Sugi Atlas →

21 patent compounds predicted against MSR1, 15 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL14075834 SCHEMBL14075834 0.55 1/20
SCHEMBL22300241 SCHEMBL22300241 0.44 1/20
SCHEMBL156333 SCHEMBL156333 0.43 1/20
SCHEMBL309480 SCHEMBL309480 0.43 1/20
SCHEMBL17627685 SCHEMBL17627685 0.43 1/20
Xanthorrizol Xanthorrizol (SCHEMBL13816855) 0.41 1/20
Xanthorrizol Xanthorrizol (SCHEMBL14115131) 0.41 1/20
Xanthorrizol Xanthorrizol (SCHEMBL14879579) 0.41 1/20
SCHEMBL16749879 SCHEMBL16749879 0.41 1/20
SCHEMBL16749882 SCHEMBL16749882 0.41 1/20
SCHEMBL29412614 SCHEMBL29412614 0.41 1/20
SCHEMBL29571282 SCHEMBL29571282 0.41 1/20
SCHEMBL29966905 SCHEMBL29966905 0.41 1/20
SCHEMBL31545696 SCHEMBL31545696 0.41 1/20
SCHEMBL27876532 SCHEMBL27876532 0.40 1/20

Clinical trials — most relevant to MSR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Rituximab in the Treatment of Graves' Disease PHASE1/PHASE2COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN PHASE2COMPLETED
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease PHASE2COMPLETED
Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis PHASE1COMPLETED
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. PHASE1UNKNOWN
Macrophage Phagocytosis in COPD nanCOMPLETED
Role of the Inflammatory Receptors in the Pathogenesis of Atherosclerosis nanUNKNOWN
Efferocytosis and Genomic Polymorphism in Autoimmune Diseases nanUNKNOWN
Macrophages, GM-CSF and MARS Proteinosis nanCOMPLETED
Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial nanUNKNOWN
Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients nanUNKNOWN
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk nanCOMPLETED
Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients nanCOMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk nanCOMPLETED
The Relationship of RAGE Gene Polymorphism With Type I Diabetes in Egyptian Patients nanCOMPLETED
The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction nanUNKNOWN
Cancer Fusion Hybrids and Desmoplasia nanUNKNOWN
Effect of Storage Condition on CD47 Expression Level in Platelet Concentrate nanUNKNOWN
Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization nanCOMPLETED
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches nanUNKNOWN
The Suppression of Toll Like Receptors by Insulin nanCOMPLETED
Effect of Alcohol Consumption on Markers of Inflammation nanCOMPLETED
Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio as Predictors of Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome nanNOT_YET_RECRUITING
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis nanCOMPLETED
Liver Transplantation and Reticuloendothelial Clearance Capacity nanCOMPLETED
Effects of Dietary Interventions on Serum and Macrophage Atherogenicity nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MSR1 binder may also engage these)

ProteinNameSimilarity
Q05585 — 1.000 Q05585 →
P30204 — 1.000 P30204 →
P21758 — 1.000 P21758 →
Q5RFW0 — 1.000 Q5RFW0 →
Q6AZY7 — 0.992 Q6AZY7 →
Q8C850 — 0.991 Q8C850 →
Q5KU26 — 0.991 Q5KU26 →
Q4V885 — 0.990 Q4V885 →
A5PMY6 — 0.990 A5PMY6 →
Q9R097 — 0.988 Q9R097 →
Q96PD2 — 0.988 Q96PD2 →
Q15389 — 0.987 Q15389 →
Q2LK54 — 0.987 Q2LK54 →
Q60FC1 — 0.987 Q60FC1 →
O08538 — 0.986 O08538 →
Q13201 — 0.986 Q13201 →
A6QP79 — 0.986 A6QP79 →
Q8K299 — 0.986 Q8K299 →
Q1RMR1 — 0.985 Q1RMR1 →
Q5XK91 — 0.985 Q5XK91 →
O18920 — 0.985 O18920 →
Q9BDY7 — 0.984 Q9BDY7 →
Q6ZMJ2 — 0.984 Q6ZMJ2 →
E9Q6D8 — 0.984 E9Q6D8 →
Q9D9J7 — 0.984 Q9D9J7 →
Q6AX44 — 0.984 Q6AX44 →
Q9DEX1 — 0.984 Q9DEX1 →
A0A8J8 — 0.984 A0A8J8 →
Q8IZF2 — 0.983 Q8IZF2 →
O35608 — 0.983 O35608 →